| P2093 | author name string | Makoto Takano | |
| | Masashi Yano | |
| | Hiroyoshi Suzuki | |
| | Koji Kawamura | |
| | Tomohiko Ichikawa | |
| | Naoto Kamiya | |
| | Takashi Imamoto | |
| | Masaharu Takanami | |
| | Makito Naoi | |
| | Takumi Endo | |
| P2860 | cites work | Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 |
| | A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function | Q24336057 |
| | RANK is essential for osteoclast and lymph node development | Q24598872 |
| | osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification | Q24603266 |
| | Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL | Q24682139 |
| | Metastatic bone disease: clinical features, pathophysiology and treatment strategies | Q28202792 |
| | Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation | Q28575953 |
| | Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach | Q33290855 |
| | Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. | Q33979879 |
| | A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma | Q34152748 |
| | Role of RANK ligand in mediating increased bone resorption in early postmenopausal women | Q34912769 |
| | Bone markers in the management of patients with skeletal metastases | Q35053972 |
| | Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone | Q39946634 |
| | The Use of Prostate-Specific Antigen in Staging Patients With Newly Diagnosed Prostate Cancer | Q40484271 |
| | Skeletal complications of malignancy | Q41637486 |
| | Osteoprotegerin and rank ligand expression in prostate cancer | Q42502915 |
| | Serum osteoprotegerin levels are increased in patients with advanced prostate cancer | Q43762995 |
| | Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan | Q44275780 |
| | A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases | Q44291815 |
| | Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate | Q44627250 |
| | Effects of gonadotropin-releasing hormone agonists on bone metabolism markers and bone mineral density in patients with prostate cancer | Q44971959 |
| | Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer. | Q47368192 |
| | Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. | Q52222276 |
| | Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor–κB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton | Q57904787 |
| | Efficacy of follow-up bone scans in carcinoma of the prostate | Q70387290 |
| | Skeletal fractures negatively correlate with overall survival in men with prostate cancer | Q74628779 |
| | Inability of bone turnover marker as a strong prognostic indicator in prostate cancer patients with bone metastasis: comparison with the extent of disease (EOD) grade | Q78108894 |
| | Biochemical markers of bone turnover in patients with localized and metastasized prostate cancer | Q79339502 |
| | Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer | Q81203149 |
| | Implications of serum bone turnover markers in prostate cancer patients with bone metastasis | Q83144596 |
| P433 | issue | 4 | |
| P921 | main subject | prostate cancer | Q181257 |
| P304 | page(s) | 366-372 | |
| P577 | publication date | 2011-02-16 | |
| P1433 | published in | International Journal of Clinical Oncology | Q15758148 |
| P1476 | title | Significance of serum osteoprotegerin and receptor activator of nuclear factor κB ligand in Japanese prostate cancer patients with bone metastasis | |
| P478 | volume | 16 | |